Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesDecoy Therapeutics Inc.

Decoy Therapeutics Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.07 USD -0.02 ( 1.83%)
Last update at 2026-11-12T15:30:00Z
VOLUME
21485
Market Cap
3.13M

Momentum Score

…

Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.05
Low
1.07
High
52 Week Price Range
5.40
Low
239.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures indicate Decoy Therapeutics Inc. is an early-stage biotechnology company focused on developing decoy-based therapeutic molecules, though publicly available information is limited. Long-term growth may be driven by clinical trial readouts, regulatory approvals, strategic partnerships and successful financing, and investors may find potential upside if the company's platform achieves clinical validation.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.09
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.15
ROE
-338.31%
Net Debt
-10.71M
ROCE
-214.20%
Diluted EPS TTM
-129.10

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.52M -5.58M -12.54M -31.61M -12.77M
Net income -12.52M -5.58M -12.54M -31.61M -12.77M
Selling general administrative 3.73M 4.96M 5.72M 7.14M 6.10M
Gross profit -8.52M -0.00M -0.01M -0.01M 1.82M
Reconciled depreciation 0.01M 0.00M 0.01M 0.01M 0.02M
Ebit - -5.73M -12.89M -22.98M -12.81M
Ebitda -12.61M -5.73M -12.88M -22.97M -12.79M
Depreciation and amortization - 0.00M 0.01M 0.01M 0.02M
Operating income -12.61M -5.73M -12.89M -31.84M -12.81M
Other operating expenses 12.61M 5.73M 12.89M 31.84M 12.81M
Interest income 0.10M 0.16M 0.35M 0.22M -
Net interest income 0.10M 0.16M 0.35M 0.22M -
Total revenue 0.00M 0.00M 0.00M 0.00M 1.84M
Total operating expenses 4.10M 5.73M 12.89M 31.84M 12.81M
Cost of revenue 8.52M 0.00M 0.01M 0.01M 0.02M
Total other income expense net 0.10M 0.16M 0.35M 0.23M 0.04M
Net income from continuing ops -12.52M -5.58M -12.54M -31.61M -12.77M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 11.06M 3.02M 6.59M 14.65M 40.83M
Other current assets 0.28M 0.55M 0.62M 0.80M 0.95M
Total liab 5.17M 1.51M 1.30M 4.27M 2.11M
Total stockholder equity 5.89M 1.51M 5.29M 10.38M 38.72M
Other current liab 1.00M 0.35M 0.41M 1.41M 0.57M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -94.44M -81.92M -76.35M -63.81M -32.20M
Good will - - - 0.00M 8.87M
Cash 10.71M 2.43M 5.90M 12.11M 29.21M
Total current liabilities 5.17M 1.51M 1.30M 4.27M 2.11M
Current deferred revenue 3.23M - - - -
Net debt -10.71M -2.21M -5.61M -12.11M -29.21M
Short term debt - 0.22M 0.29M - -
Short long term debt - 0.22M 0.29M - -
Short long term debt total - 0.22M 0.29M - -
Other stockholder equity 100.33M 83.44M 81.63M 74.19M 70.92M
Total current assets 10.99M 2.99M 6.52M 14.52M 30.16M
Net receivables - - - 1.61M -
Accounts payable 0.94M 0.94M 0.60M 2.86M 1.54M
Non currrent assets other 0.03M 0.04M 0.07M 0.13M 0.19M
Non current assets total 0.07M 0.04M 0.07M 0.13M 10.67M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total cashflows from investing activities 0.76M - - -1.50M -
Net borrowings -0.22M -0.47M -0.28M 0.00M -0.48M
Total cash from financing activities 12.34M 1.06M 6.64M 1.99M 28.30M
Net income -12.52M -5.58M -12.54M -31.61M -12.77M
Change in cash 8.28M -3.47M -6.21M -17.11M 18.10M
Begin period cash flow 2.43M 5.90M 12.11M 29.21M 11.12M
End period cash flow 10.71M 2.43M 5.90M 12.11M 29.21M
Total cash from operating activities -4.83M -4.53M -12.85M -17.60M -10.20M
Issuance of capital stock 12.56M 1.53M 6.92M 1.99M 27.29M
Depreciation 0.01M 0.00M 0.01M 0.01M 0.02M
Other cashflows from investing activities -0.58M - 0.00M -1.50M -
Change to account receivables - - 1.48M - 2.25M
Other cashflows from financing activities 12.34M - - - 1.49M
Capital expenditures 0.58M 0.00M 0.00M 1.50M 0.00M
Change in working capital -1.05M 0.77M -0.97M 2.37M 2.03M
Stock based compensation 0.22M 0.27M 0.52M 0.80M 0.56M
Other non cash items 7.47M 0.27M 0.13M 10.84M -0.04M
Free cash flow -4.83M -4.53M -12.85M -19.10M -10.20M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DCOY
Decoy Therapeutics Inc.		 -0.02
1.83%		 1.07 - - 15.86 0.54 72.64 1.52
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Decoy Therapeutics Inc.

Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.

One Broadway, Cambridge, MA, United States, 02142

https://decoytx.com

11

Name Title Year Born
Mr. Mark J. Rosenblum CPA Executive VP & CFO 1953
Mr. Frederick E. Pierce II CEO & Director 1962
Dr. Barbara Hibner Ph.D. Chief Scientific Officer & Director 1961
Dr. Nadeem Q. Mirza M.D., M.P.H. Senior Vice President of Clinical Development NA
Mr. Peter K. Marschel M.B.A., M.S. Chief Business Officer 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…